Results 71 to 80 of about 1,242 (177)

[Experience with topical brimonidine (Alphagan (R) 0,2%) in the treatment of glaucomas]

open access: yes, 2000
Purpose: The main purpose of our study was to assess the systemic safety of brimonidine tartrate 0.2 %, an alpha 2 highly selective agonist in patients with glaucoma or ocular hypertension Material-Methods: Brimonidine was administered alone or in ...
Dutrieux, C, Detry-Morel, M.
core  

Underuse of Pharmacologic Therapies for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Before Specialist Evaluation. [PDF]

open access: yesAnn Fam Med
Grach SL   +7 more
europepmc   +1 more source

Hyperadrenergic Postural Tachycardia Syndrome: Clinical Biomarkers and Response to Guanfacine. [PDF]

open access: yesHypertension
Okamoto LE   +11 more
europepmc   +1 more source

A Case of Labile BP in a Patient With Oropharyngeal Carcinoma. [PDF]

open access: yesChest
Golbin JM   +4 more
europepmc   +1 more source

Sympatholytic Agents

open access: yes, 2017
Yury Khelemsky   +2 more
openaire   +1 more source

From woozy to well: a primary care approach to orthostatic hypotension. [PDF]

open access: yesSingapore Med J
He H, Yang C, How CH, Quah JHM.
europepmc   +1 more source

Traitement des glaucomes par la brimonidine (Alphagan 0.2%).

open access: yes, 2000
PURPOSE: The main purpose of our study was to assess the systemic safety of brimonidine tartrate 0.2%, an alpha 2 highly selective agonist in patients with glaucoma or ocular hypertension Material-Methods: Brimonidine was administered alone or in ...
Dutrieux, C, Detry-Morel, M.
core  

Home - About - Disclaimer - Privacy